Standard Operating Procedures (SOPs) for. Clinical Research Personnel Part 16. Summary
|
|
- Quentin Wiggins
- 6 years ago
- Views:
Transcription
1 Standard Operating Procedures for Clinical Research Personnel Part 16 Wendy Bohaychuk and Graham Ball GCRP Consultants, Lakehurst General Delivery, Ontario, Canada KOL 2JO Summary This is the 16th in a series of articles containing proposals for wording and content of Standard Operating Procedures (SOPs) for clinical research activities conducted by sponsors and Contract Research Organisations (CROs). The procedures include those required by the International Conference on Harmonisation (ICH), the Food and Drug Administration (FDA), many other guidelines and regulations, and best practice observed by the authors. The model forms require modification for actual use. In this article, SOPs are presented for internal review of case report forms and data: initial internal CRF review (after retrieval to sponsor/cro) (SOP 405); data correction after retrieval from study sites (SOP 406); database development, review and lock (SOP 407); and statistical review (SOP 408). SOPs are also presented for management of CROs (SOP 409) and clinical laboratories during studies (SOP 410). (The full text of all 101 SOPs is available from the authors.) Copyright 2003 John Wiley & Sons, Ltd. Key Words GCP; SOP; data tracking; data query SOP 405. Initial Internal CRF Review (After Retrieval to Sponsor/CRO) Policy Immediately upon retrieval of CRFs to the sponsor/cro premises, the CRFs must be reviewed Correspondence to: Wendy Bohaychuk, GCRP Consultants, Lakehurst General Delivery, Ontario, Canada KOL 2JO wbohaychuk@gcrpc.com internally to determine any further clarification and resolution of data which might be necessary. (This SOP includes procedures which require the involvement of clinical research personnel. It must not supersede SOPs developed by personnel in the data management department.) Procedures Sponsor/CRO personnel must not make any entries on original top white copies of CRFs retrieved to the sponsor/cro site (or on copies of CRFs at the investigator site) except on designated areas Upon retrieval to the sponsor/cro premises, the top white copy of the CRF will immediately be sent to the archives by the [Monitor]. Thereafter, all personnel will only work with the middle working copy of the CRF The [Monitor] will maintain a record of distribution of all CRFs on the CRF tracking form (Form 405-1) The CRFs will first be reviewed by another [Monitor] (ie secondary monitoring) using the CRF internal review form (Form 405-2) which will initially be completed by the primary [Monitor] The CRF internal review form must accompany the CRF during all subsequent review If AEs are observed on retrieved CRFs, the CRFs must be sent to the [Medical Safety Advisor] of the sponsor/cro within two working days. [The [Medical Safety Advisor] will then be responsible for further distribution of the CRF with the attached internal CRF review form.] DOI: /qaj.222
2 Standard operating procedures for clinical research personnel If serious AEs are observed on retrieved CRFs, the CRFs must immediately (within 24 hours) be sent for review by the [Medical Safety Advisor]. (The [Medical Safety Advisor] will then be responsible for further distribution of the CRF and attached internal CRF review form.) Questions about eligibility and evaluability which might affect the statistical analysis require further review by the [Biostatistician] which should also be documented on Form CRFs must be reviewed by all responsible reviewers in the clinical research department within three working days of retrieval from the investigator site. [This time period may vary, of course. Again, the objective is to review data as promptly as possible.] After review by clinical research personnel, the CRFs and the completed attached Form will be transmitted to the data processing department by the [Monitor] Data recorded on CRFs will be entered into the computer within ten working days of being received by the data processing group. [Again, this time period may vary. There should be separate data management SOPs to deal with this requirement in more detail.] After the data are entered into the computer, any questions concerning the data should be sent to the [Monitor] who will, if necessary, contact the investigator for correction of the data, according to the procedures described in SOP The [Monitor] must inform the [Title] of all relevant information (eg CRFs undergoing review) that must be entered into the clinical study tracking schedule in accordance with SOP Forms and will be filed by the [Monitor] in the sponsor/cro study site archives. [Depending on how the database is being handled, it might also be wise to file these forms in the sponsor/ CRO study archives.] Related SOPs: SOP 401. Monitoring Visits, SOP 403. Source Documents versus Case Report Forms, SOP 404. Source Data Verification and CRF Review at Study Sites, SOP 406. Data Correction After Retrieval from Study Sites, SOP 407. Database Development, Review and Lock, SOP 408. Statistical Review SOP 602. Recording and Reporting Adverse Events. Suggestions for Forms: Documentation of Internal Safety Review of CRFs, List of Protocol Violations. Form CRF Tracking Please complete a separate form for each CRF. Please provide a comment for all NO and NA (Not Applicable) responses. Please attach a copy of the form to the CRF. Sponsor/CRO name: Study medication/device name: Project name/code number: Study/protocol number: Study/protocol version number and date: (dd/mmm/yy) Study/protocol title:
3 102 W. Bohaychuk and G. Ball (Form designer: prepare the following items in a column format.) Study subject s initials: Study subject s number/code: CRF number: Study visit days/numbers: Study visit dates: (dd/mmm/yy) Date CRF received by sponsor/cro: (dd/mmm/yy) Date CRF sent to data processing group: (dd/mmm/yy) Original top (white) copy sent to archives: Secondary monitoring review undertaken: Safety review undertaken: Biostatistician review undertaken: DQF required: DQF issued: Responsibility for completion of form: name, title, signature, date (dd/mmm/yyyy) Distribution: Medical Safety Advisor, Data Management Department Archiving: Sponsor/CRO Study Site Archives Form Internal CRF Review Please complete a separate form for each CRF. Please provide a comment for all NO and NA (Not Applicable) responses. Please attach a copy of this form to the CRF. Sponsor/CRO name: Study medication/device name: Project name/code number: Study/protocol number: Study/protocol version number and date: (dd/mmm/yy) Study/protocol title: Study subject s initials: Study subject s number/code: CRF number: Study visit days/numbers: Study visit dates: (dd/mmm/yy) This form should initially be completed by the [Monitor]. Other reviewers may comment on the initial entries in the space provided below. Is study subject eligible? Specify protocol violations affecting eligibility: Other reviewer comments: Is study subject evaluable for safety? Specify protocol violations affecting safety evaluability: Other reviewer comments:
4 Standard operating procedures for clinical research personnel 103 Is study subject evaluable for effectiveness? Specify protocol violations affecting effectiveness evaluability: Other reviewer comments: Did the study subject complete the study? If not, specify the reasons for premature termination: Other reviewer comments: Were AEs noted? If yes, notify the [Medical Safety Advisor] within two working days. Specify the AEs: Other reviewer comments: Were SAEs noted? If yes, notify the [Medical Safety Advisor] immediately. Specify the SAEs: Other reviewer comments: Did the study subject withdraw due to AEs? Specify the AEs resulting in withdrawal: Other reviewer comments: Did the study subjects withdraw due to ineffectiveness of the study medication/device? Specify: Other reviewer comments: Is the study subject a dropout? Other reviewer comments: Is data resolution requested? If yes, attach DQF. (Specify DQF numbers.) Other reviewer comments: Primary [Monitor] review: name, title, signature, date (dd/mmm/yyyy) Secondary [Monitor] review: name, title, signature, date (dd/mmm/yyyy) [Medical Safety Advisor] review: name, title, signature, date (dd/mmm/yyyy) Biostatistician review: name, title, signature, date (dd/mmm/yyyy) Data management review: name, title, signature, date (dd/mmm/yyyy) Responsibility for completion of form: name, title, signature, date (dd/mmm/yyyy) Supervisor review: name, title, signature, date (dd/mmm/yyyy) Supervisor comments if there are disagreements between reviewers: Distribution: Medical Safety Advisor, Data Management Department, Statistics Department Archiving: Sponsor/CRO Study Site Archives SOP 406. Data Correction After Retrieval from Study Sites Policy To ensure that the integrity of clinical research data is maintained and that there is total agreement between the data recorded on CRFs (and data query forms [DQFs]), the data entered on the computer, the data recorded in data listings and cross tabulations, the data entered into statistical and clinical study reports, and finally the data in the sponsor/cro and investigator archives, it is essential that the data must only be changed by following a formal procedure. Sponsor/CRO personnel may not make any unauthorised changes to data: all data changes must be authorised by the investigator. After the CRFs have been reviewed at the investigator site, and signed and dated by the investigator, and returned to the sponsor/cro, the data contained within these CRFs will not be changed except by means of a documented data correction
5 104 W. Bohaychuk and G. Ball procedure. [This SOP includes procedures which require the involvement of clinical research personnel. It must not supersede SOPs developed by personnel in the data management department.] [The correction procedure described in this SOP is followed by many companies. However, there are other ways of achieving the same goal.] Procedures Requests for data clarification and resolution must be documented on a DQF, Form 406-1, which will be issued by the [Monitor] within five working days of retrieval of the CRFs to the sponsor/cro premises or issued by the data processing personnel within eight working days of receipt of the CRFs from the clinical research personnel. [These time periods may vary within a specific organisation: however, data must always be processed promptly.] The DQF will be printed on three-part NCR paper, with completed copies ultimately designated for: [Some companies use four-part forms to save on extra photocopying and to provide a working copy for the monitors.] Sponsor/CRO study site archives (original copy); Investigator study site archives (bottom copy); Data processing personnel (middle copy) The DQF must be taken by the [Monitor] to the study site for completion and signature by the investigator. (If sent by post, the [Monitor] must subsequently visit the study site to verify the data resolution. Verification by the [Monitor] will be confirmed on the DQF.) The [Monitor] will use a DQF tracking form (Form 406-2) to document movement of the DQF After completion and signature by the investigator, the bottom copy of the DQF should be retained with the investigator copy of the CRF at the study site The (top) white original and second copies must be returned to the sponsor/cro. The (top) white original copy will immediately be archived, with the original relevant CRF pages The second copy of the DQF will be forwarded for use by data entry and data processing personnel immediately after secondary review by the [Title] Data entry can occur before an investigator signature is obtained on the DQF. However, the database cannot be locked until all signed and dated DQFs are received and verified The [Monitor] must inform the [Title] of all relevant information (e.g. data queries issued, reviewed) that must be entered into the clinical study tracking schedule in accordance with SOP The [Monitor] is responsible for filing Forms and in the sponsor/ CRO study archives. Related SOPs: SOP 401. Monitoring Visits, SOP 404. Source Data Verification and CRF Review at Study Sites, SOP 405. Initial Internal CRF Review (After Retrieval to Sponsor/CRO), SOP 407. Database Development, Review and Lock, SOP 408. Statistical Review Suggestions for Forms: Documentation of Secondary Review of DQFs. Form Data Query Forms (DQFs) Sponsor/CRO name: Study medication/device name: Project name/code number:
6 Standard operating procedures for clinical research personnel 105 Study/protocol number: Study/protocol version number and date: (dd/mmm/yy) Study/protocol title: DQF number: Date of issue of DQF to study site: (dd/mmm/yy) CRF number: Study subject number/code: Randomisation number: Study subject initials: Study site number: Investigator name: Monitor name: Originator of DQF: name, title, signature, date (dd/mmm/yyyy) (Form designer: prepare the following items in a column format.) CRF page: Item requiring clarification: Correction: (To be completed by study site personnel) Reason for correction: (To be completed by study site personnel) I have reviewed and approved all the queries noted above: name, title, signature, date (dd/mmm/yyyy) Source data verification conducted by: name, title, signature, date (dd/mmm/yyyy) Responsibility for completion of form: name, title, signature, date (dd/mmm/yyyy) Supervisor review: name, title, signature, date (dd/mmm/yyyy) Distribution: Data Management Department Archiving: Sponsor/CRO Study Site Archives, Investigator Study Site Archives Form DQF Tracking Please provide a comment for all NO and NA (Not Applicable) responses. Sponsor/CRO name: Study medication/device name: Project name/code number: Study/protocol number: Study/protocol version number and date: (dd/mmm/yy) Study/protocol title: (Form designer: prepare the following items in a column format.) Study subject number/code: DQF number: Date of issue of DQF to study site: (dd/mmm/yy) DQF issued by: (initials) Date completed DQF received by sponsor/cro: (dd/mmm/yy) Date completed DQF sent to data processing group: (dd/mmm/yy)
7 106 W. Bohaychuk and G. Ball Original top (white) copy sent to archives: Secondary monitoring review undertaken: Safety review undertaken: Biostatistician review undertaken: Further query required: [If further query is required, the same process noted in this SOP must be repeated.] New DQF issued: Responsibility for completion of form: name, title, signature, date (dd/mmm/yyyy) Supervisor review: name, title, signature, date (dd/mmm/yyyy) Distribution: Medical Safety Advisor, Data Management Department Archiving: Sponsor/CRO Study Site Archives SOP 407. Database Development, Review and Lock Policy Data recorded on computer databases must accurately reflect data contained in the CRFs. Clinical research personnel must co-operate with the data management group to ensure that this is achieved. [This SOP includes procedures which require the involvement of clinical research personnel. It must not supersede SOPs developed by personnel in the data management group.] Procedures Prior to study subject enrolment, the following activities should be undertaken: The [Title] in the clinical research department will be provided with the opportunity to review and comment upon the data management plan, the data management manuals, and the proposed structure of the database. A copy of the final protocol with attachments (e.g. CRF, diary cards, psychological tests, quality of life forms, etc.) will be sent to the data processing personnel, by the [Title] in the clinical research department, to facilitate the preparation of data entry screens. Data entry screens will be tested by the [Title] in the clinical research department and by the data processing personnel by entry of data from a test set. This process will also help the development of any particular instructions that must be given to the data processing personnel by the [Title] in the clinical research department, and vice versa After data entry has begun, verification of the data listings (compared to the data in the CRF) will require review by the [Title] in the clinical research department. Any new queries or errors detected during review of the listings must be sent to the data entry personnel If, as a result of the review of the data listings, the [Title] in the clinical research department or data processing personnel determine that further data queries must be issued to the investigator, this procedure must be undertaken in accordance with SOP The data conventions (e.g. the variations to protocol requirements which will be permitted for statistical analysis) will normally be determined during the development of the protocol. Further refinement of the definitions of data conventions may arise during the performance of the study.
8 Standard operating procedures for clinical research personnel All proposed data conventions, with reasons, are to be discussed and agreed in a formal meeting which should be documented. A [Biostatistician] must also approve all final decisions Final data conventions will be established and documented in Form before the statistical analysis of the study Study subject classification (e.g. the final determination of eligibility and evaluability within the limits of the data conventions) will be determined and documented after clinical completion of the study, but prior to unmasking (in the case of a double-masked study). The following must be considered in determining study subject classifications: After data correction procedures have been completed, and just prior to statistical analysis, all issues relating to inclusion/exclusion of study subjects for analysis must be resolved to enable formal study subject classification to be achieved. Data listings (masked) to treatment allocation, of all protocol violations and copies of the final agreed data conventions form (Form 407-1) will be issued to all individuals responsible for determining final study subject classifications. If a protocol violation falls within the limits of the data conventions, the study subjects may be considered to be eligible and/or evaluable (whichever is being assessed). If a protocol violation falls outside the limits of the data conventions, the study subjects will be assessed on a subject-by-subject basis for eligibility and evaluability All study subject classifications, with reasons, are to be discussed and agreed in a formal meeting which should be documented. A [Biostatistician] must also approve all final decisions A final masked study subject classification document which lists acceptability for safety and effectiveness analyses will be prepared and documented in a study subject classification form (Form 407-2), after all questions regarding protocol violations have been resolved When the database has been declared to be clean (i.e. all data corrections have been completed and authorised) by the data processing group and has been formally locked, the database will be released to the [Biostatistician] for the final statistical analysis (SOP 408). The clinical research personnel must be informed of the locking procedure After locking, further access to the data in the database will be denied, unless a formal authorization is documented by the [Title] The [Monitor] must inform the [Title] of all relevant information (e.g. CRFs entered on the database, number of clean CRFs) that must be entered into the clinical study tracking schedule in accordance with SOP The [Title] must inform the [Title] of all relevant information (e.g. data conventions and subject classification agreed, database clean, database locked, database released for analysis and display) that must be entered into the clinical study tracking schedule in accordance with SOP The [Monitor] will ensure that Forms and are filed in the sponsor/cro study archives. Form must also be filed in the sponsor/cro study site archives. Related SOPs: SOP 401. Monitoring Visits, SOP 404. Source Data Verification and Review at Study Sites, SOP 405. Initial Internal CRF Review (After Retrieval to Sponsor/CRO), SOP 406. Data Correction after Retrieval from Study Sites, SOP 408. Statistical Review.
9 108 W. Bohaychuk and G. Ball Suggestions for Forms: Data Management Plan Review, Data Management Manual Review, Data Entry Screen Review, Data Entry Procedures Review, Verification of Data Listings, Documentation of Data Conventions Meeting, Documentation of Study Subject Classification Meeting, Authorization to Lock Database, Notification of Locked Database, Request to Change (Unlock) Database, List of Changes to Database, Authorization of Final Approved Database, Authorization for Database Release for Biometrical Evaluation [Most of these forms should probably be developed by personnel in the data management department with appropriate expertise. Clinical research personnel may provide some input to development of the forms.] Form Data Conventions Sponsor/CRO name: Study medication/device name: Project name/code number: Study/protocol number: Study/protocol version number and date: (dd/mmm/yy) Study/protocol title: Date of data conventions meeting: (dd/mmm/yy) (Form designer: prepare the following items in a column format.) Data item/variable: Protocol limits: Acceptable extension to protocol limits: Reason: Authorization of data conventions: Clinical research department: name, title, signature, date (dd/mmm/yyyy) Data management department: name, title, signature, date (dd/mmm/yyyy) Biostatistician: name, title, signature, date (dd/mmm/yyyy) Archiving: Sponsor/CRO Study Archives Form Study Subject Classification Sponsor/CRO name: Study medication/device name: Project name/code number: Study/protocol number: Study/protocol version number and date: (dd/mmm/yy) Study/protocol title: Study site number: Investigator name: Date of study subject classification meeting: (dd/mmm/yy) (Form designer: prepare the following items in a column format.)
10 Standard operating procedures for clinical research personnel 109 Study subject number: Data item/variable: Description of variation: Violation of protocol limits: Within data conventions: Eligible: Reason: Evaluable: Reason: Authorization of study subject classifications: Clinical research department: name, title, signature, date (dd/mmm/yyyy) Data management department: name, title, signature, date (dd/mmm/yyyy) Biostatistician: name, title, signature, date (dd/mmm/yyyy) Archiving: Sponsor/CRO Study Archives, Sponsor/CRO Study Site Archives SOP 408. Statistical Review Policy Statistical review and analysis of all clinical study data must be undertaken in conjunction with preparation of a final clinical report. Clinical research personnel must co-operate with the data management and statistics department to ensure that this is achieved. [This SOP includes procedures which require the involvement of clinical research personnel. It must not supersede SOPs developed by personnel in the data management department and the statistics department.] Procedures The statistical analysis plan for a clinical study will be written by the [Biostatistician] responsible for the analysis of the study in consultation with the clinical team, prior to the issue of the final approved protocol The [Title] in the clinical research department must review and approve the statistical analysis plan A synopsis of the statistical analysis plan should be included in the protocol The statistical analysis of a study may only commence after the study has been completed and the data are clean (SOP 407). Any exceptions (i.e. interim analyses) must be documented with reasons The [Title] in the clinical research department must provide the [Biostatistician] with a subject-by-subject listing of evaluability to specify in which forms of analyses each subject may be included (eg intent-to-treat, valid case, per protocol, special case, etc) In the case of masked studies, the randomisation schedule will be released to the [Biostatistician] after the statistical analyses of masked groups have been completed in order that assignment of treatments to the study populations can be completed After the statistical analysis report has been completed, it will be issued with the signed and dated approval of the [Biostatistician]. The approval of the [Biostatistician] implies that: all data have been included in the analysis and any exclusions have been clearly stated in the report; data have been accurately tabulated and summarised; all listings, tables and graphs in the report are correct; and the statistical methodology is correct The [Title] in the clinical research department must review and approve the statistical analysis report which may then be released for preparation of the final clinical report (SOP 703).
11 110 W. Bohaychuk and G. Ball The [Title, statistics department] must inform the [Title] of all relevant information (e.g. interim analysis conducted, statistical analysis plan prepared and agreed, statistical analysis undertaken, statistical report prepared, reviewed and agreed) that must be entered into the clinical study tracking schedule in accordance with SOP The statistical analysis plan and the statistical analysis report must be archived by the [Title] in the sponsor/cro study archives. Related SOPs: SOP 304. Preparation of Protocols, SOP 405. Initial Internal CRF Review (After Retrieval to Sponsor/CRO), SOP 406. Data Correction after Retrieval from Study Sites, SOP 407. Database Development, Review and Lock, SOP 513. Revealing Randomisation Code Assignments After Study Completion, SOP 703. Preparation of Clinical Study Reports. Suggestions for Forms: Format of Statistical Analysis Plans, Statistical Analysis Plan Review, Statistical Analysis Plan Approval, Recipients of Statistical Analysis Plans, Eligibility Listing of Study Subjects, Format of Statistical Analysis Reports, Statistical Analysis Report Review, Statistical Analysis Report Approval, List of Recipients of Statistical Analysis Reports [Most of these forms should probably be developed by personnel in the statistics department with appropriate expertise. Clinical research personnel may provide some input to development of the forms.] SOP 409. Management of Contract Research Organisations During Studies Policy During a clinical study, further management of the CRO (including Phase I facilities) is necessary to ensure the progress of the study in a timely and efficient manner. Procedures It is the responsibility of the assigned [Title] to maintain contact with the CRO on a regular and frequent basis (at least weekly) to ensure that the study is being conducted in accordance with the contract Contacts will involve visits to the CRO and randomly selected investigator sites. Telephone contact reports and all other correspondence will also be archived The [Title] will record observations about the conduct of the CRO during the study, and will particularly address the following items: Changes, if any, in personnel, and additional training of personnel; Changes, if any, in equipment; Promptness of distribution of progress reports and CRO visit reports to study sites; Promptness of reporting of significant events to sponsor, study sites, ethics committees and regulatory authorities (e.g. adverse events, protocol amendments); Maintenance of quality control systems Any deficiencies observed in the conduct of the study will be reported immediately in writing to the [Title] who will determine the corrective action required The [Title] must inform the [Title] of all relevant information (e.g. significant event or changes) that must be entered into the clinical study tracking schedule in accordance with SOP All correspondence and documentation of review of CRO activities will be filed by the [Title] in the sponsor study archives. (The CRO should also archive the same documentation.) Related SOPs: SOP 326. Selection of Contract Research Organisations.
12 Standard operating procedures for clinical research personnel 111 Suggestions for Forms: List of Items Provided to CROs Prior to Study Initiation, Initiation Visits to CROs, Monitoring Visits to CROs During Studies, Documentation of CRO Telephone Contacts, Assessment of CRO Compliance with Contracts. SOP 410. Management of Clinical Laboratories During Studies Policy During a clinical study, further management of the clinical laboratory is necessary to ensure the progress of the study in a timely and efficient manner. Procedures It is the responsibility of the assigned [Title] to maintain contact with the clinical laboratory on a regular and frequent basis (at least once a month) to ensure that the study is being conducted in accordance with the contract Contacts will involve visits to the clinical laboratory. Telephone contact reports and all other correspondence will also be archived The [Title] must provide the clinical laboratory with: name, address, telephone and fax number of each investigator and study site; and name, address, telephone and fax number of the sponsor/cro monitor. Contact numbers provided must be available on a 24-hour basis The [Monitor] must arrange for attendance of clinical laboratory personnel at startup meetings (or individual site initiation visits) to demonstrate use of all items for the collection, storage and shipment of samples, and the management of clinical laboratory reports The [Monitor] must work with the clinical laboratory to provide appropriate information to investigators such as: Routine and special procedures or equipment for collecting, handling, storing, packaging and shipping clinical samples; Sample request forms with instructions for completion; Labels with instructions for use; Procedures to report test results; Procedures for clinically significant results; Contact names and addresses The [Title] will record observations about the conduct of the clinical laboratory during the study, and will particularly address the following items: Changes, if any, in the clinical laboratory protocol; Changes, if any, in reference ranges; Changes, if any, in personnel; Changes, if any, in equipment; Promptness of sample management, with regard to: Receipt; Analysis; Issue of laboratory report; Promptness of reporting significant out-of-range values to sponsor/ CRO; Promptness of reporting significant out-of-range values to investigators; Maintenance of quality control systems; Maintenance of accreditation and certification Any deficiencies observed in the conduct of the study will be reported immediately in writing to the [Title], who will determine the corrective action required The [Monitor] must inform the [Title] of all relevant information (e.g. collection of samples, changes in procedures) that must be entered into the clinical study tracking schedule in accordance with SOP 109.
13 112 W. Bohaychuk and G. Ball The [Monitor] is responsible for ensuring that all correspondence and documentation of review of the clinical laboratory will be filed in the sponsor/cro study archives. (The clinical laboratory should also archive the same documentation.) Related SOPs: SOP 327. Selection of Clinical Laboratories, SOP 328. Study Site Initiation Visits, SOP 329. Study Startup Meetings for Multicentre Studies, SOP 514. Management of Clinical Laboratory Samples. Suggestions for SOPs: Clinical Laboratory Protocols Suggestions for Forms: List of Items Provided to Clinical Laboratories Prior to Study Initiation, Initiation Visits to Clinical Laboratories, Monitoring Visits to Clinical Laboratories During Study, Documentation of Clinical Laboratory Telephone Contacts.
Investigator Site File Index (Medical Devices)
Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol (Clinical Investigation Plan) Current version plus all previous versions (or provide file note
More informationESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL
Assemble Essential Documents in Trial Master File (TMF) Appendix 1 ESSENTIAL DOCUMENTS FOR THE CONDUCT OF A CLINICAL TRIAL 8.2 Before the Clinical Phase of the Trial Commences During this planning stage
More informationThe European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:
The European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197221/2005 Procedure no.: INS/GCP/3/IV ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA: SPONSOR
More informationSTANDARD OPERATING PROCEDURE. STH Researcher. Investigator Site File
Research Department STANDARD OPERATING PROCEDURE STH Researcher SOP History CSUH 00/016 SOP Number A116 Created STH Research Department (TL) Reviewed by STH Research Department (AL) 06 August 2009 Superseded
More informationInvestigator Site File Index (CTIMP)
Study Title: Site Name/Number: REC Reference Number: Sponsor Reference Number: EudraCT Number: 1. Protocol Current version plus all previous versions (or provide file note to detail location of previous
More informationAudit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.
Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd. Copyright 2009 - Pharmaceutical Research & Manufacturers Association 1 Overview Audit ICH-GCP,
More informationLOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE. Loughborough University (LU) Research Office
LOUGHBOROUGH UNIVERSITY RESEARCH OFFICE STANDARD OPERATING PROCEDURE Loughborough University (LU) Research Office SOP 1024 LU Study Closedown and End of Study Reporting for NHS Research Sponsored by Loughborough
More informationLouise Brook Clinical Trials Quality Monitor. Date
Details: Author: Louise Brook Clinical Trials Quality Monitor SOP Pages: 12 Version No. of replaced SOP: Effective date of replaced SOP: NA NA Approval: Version No: of the SOP being approved. Name of person
More informationStudy Files and Filing
Study Files and Filing The current version of all Hillingdon Hospital R&D Guidance Documents and Standard Operating Procedures are available from the R&D Intranet and Internet sites: www.ths.nhs.uk/departments/research/research.htm
More informationSTANDARD OPERATING PROCEDURE FOR RESEARCH. 17. Study Close Down
Basildon and Thurrock University Hospitals NHS FT Research & Development APPROVED STANDARD OPERATING PROCEDURE FOR RESEARCH 1. BACKGROUND 17. Study Close Down According to ICH Good Clinical Practice (GCP)
More informationESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL
ESSENTIAL DOCUMENTS DURING THE CLINICAL CONDUCT OF THE TRIAL THIS INFORMATION SHEET (ISR-RG-014) HAS BEEN TAKEN DIRECTLY FROM THE ICH- GUIDELINE* WITH ADDITIONAL COMMENTS ADDED BY THE RESEARCH GOVERNANCE
More informationStephanie Gentilin, CCRA
Elements of Clinical Trial Quality Assurance Stephanie Gentilin, CCRA Regulatory Coordinator SCTR SUCCESS Center QA Monitor NIDA Monitor s Responsibilities ICH E6 Section 5.18 Overall Purpose of Monitoring
More informationOnce notified of the end of trial, a Research Manager, on behalf of the Sponsor, will contact the CI to arrange a close down monitoring visit.
1. INTRODUCTION This SOP has been produced in accordance with the requirements of The Medicines for Human Use (Clinical Trials) Regulations 2004, Medicines for Human Use (Clinical Trials) Amendment Regulations
More informationConducting and reporting a GCP Inspection. Gunnar Danielsson Medical Products Agency
Conducting and reporting a GCP Inspection Gunnar Danielsson Medical Products Agency Preparation for an inspection Inspection plan Create worksheets for the inspection general project specific study specific
More informationGCP Basics - refresher
p. 01 GCP Basics - refresher Agenda: p. 02 Brief History of GCP GCP Regulations Principles of ICH E6 Sponsor Responsibilities Computer Systems Common Compliance Issues Brief History of GCP 3 Brief History
More informationAnnex IV to guidance for the conduct of good clinical practice inspections sponsor and CRO
23 August 2017 EMA/431267/2016 Annex IV to guidance for the conduct of good clinical practice inspections sponsor Adopted by GCP Inspectors Working Group (GCP IWG) 29 November 2017 Keywords GCP inspection,
More informationStandard Operating Procedures (SOP) Research and Development Office
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: Essential Documentation and Creation and Maintenance of Trial Master File SOP Number: 13 Version Number: 2.0 Supercedes:
More informationRESEARCH AUDIT Standard Operating Procedure
Reference Number: UHB 236 Version Number: 2 Date of Next Review: 17 th Oct 2020 Previous Trust/LHB Reference Number: N/A RESEARCH AUDIT Standard Operating Procedure Introduction and Aim As a legal Sponsor
More informationTopics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities
Topics summarised in this presentation are: method for defining quality level you want meaning of external controls quality assurance activities audit, audit report and CAPA 1. QUALITY must be guaranteed,
More informationStandard Operating Procedure
Standard Operating Procedure Title: Clinical Site Monitoring Status: PRIVATE Author Name: Audrey Strader Approver Name: Christine Kubiak Document no.: CSM 02 Effective date: 11/01/2016 Review Date (if
More informationQuality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits
Quality Assurance QA 601.01 STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits Approval: Nancy Paris, MS, FACHE President and CEO 24 May 2017 (Signature and Date) Approval: Frederick
More informationStandard Operating Procedure. GCP Auditing of Research Studies
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-16-003 GCP Auditing of Research Studies SOP effective: 09 June 2017 Review date: 09 June 2019 SOP author signature: SIGNED COPY HELD WITHIN
More informationR&D Administration Manager. Research and Development. Research and Development
Document Title: Document Number: Trial Closure and End of Trial SOP021 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D Administration
More informationQuality Assurance in Clinical Trials
Quality Assurance in Clinical Trials Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 5th, 2011 1 Introduction: quality in clinical research in human subjects Regulatory requirements:
More informationPROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP. Ad Hoc PhV Inspectors Working Group
European Medicines Agency Inspections London, 20 April 2009 EMEA/INS/PhV/85058/2008 Procedure no: INS/PhV-V/2 PROCEDURE FOR CONDUCTING PHARMACOVIGILANCE INSPECTIONS REQUESTED BY THE CVMP Ad Hoc PhV Inspectors
More informationCompliance and Quality Monitoring: What, Why, When, and How
Compliance and Quality Monitoring: What, Why, When, and How Jeanna Julo, BA, BA, CCRP Assistant Director, Clinical Data Management & Quality Controls, Auditing & Training Research Institute, University
More informationHuman Research Protection Program Policy
Adopted: 11/2005 Revised: 03/2014 Page: 1 of 6 RIGHTS AND RESPONSIBILITIES OF PRINCIPAL INVESTIGATORS IN HUMAN SUBJECTS RESEARCH POLICY Each research study will have a Principal Investigator (PI) and may
More informationRDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs. Greater Manchester Mental Health NHS Foundation Trust
RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs Greater Manchester Mental Health NHS Foundation Trust Title of Standard Operating Procedure: RDSOP16 Writing a GCP Compliant Protocol for Non-CTIMPs
More informationMulti-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18
Multi-Site Coordination Process Drafted by: Ester Dimayuga Page 1 of 18 MULTI-SITE COORDIATIO (MSC) REGULATOR PROCESS CTO-Regulatory notifies MSC of trial with UMCC as coordinating center MSC prepares
More informationTrial Master File. SOP No. SOP 7
Trial Master File SOP Title Trial Master File SOP No. SOP 7 Author Consultation Departments Date approved Julia Farmery Lincolnshire Clinical Research Facility, Research and Development, Trust consultants
More informationStandard Operating Procedure
Standard Operating Procedure Number: UM/UoM TMF/SOP08/6.0 Title: The Creation and Maintenance of Trial Master Files and Essential Documentation Version: 6.0 () Effective Date: Author: Mrs Catherine Barrow
More informationData Quality and Integrity: From Clinical Monitoring to Marketing Approval
Data Quality and Integrity: From Clinical Monitoring to Marketing Approval Nancy Detich, Ph.D., C.C.R.P. Senior Scientist, Clinical Strategy 18 November 2010 1 Objectives Identify the importance of accuracy,
More informationSTANDARD OPERATING PROCEDURE SOP 410. Set up and Initiation of an Investigator Site
STANDARD OPERATING PROCEDURE SOP 410 Set up and Initiation of an Investigator Site Version 1.2 Version date 4.01.2017 Effective date 5.07.2017 Number of pages 13 Review date July 2019 Author Role NNUH
More informationStandard Operating Procedure for Archiving
Standard Operating Procedure for Archiving SOP name: NWORTH07/19 archiving Version 2 Authorship Team: Angela Gliddon & Rhiannon Whitaker Meeting date reviewed 16 th April 2008 Designated NWORTH member
More informationFRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up?
FRAMEWORK OF CHARACTERISTICS OF A QUALIFIED SITE TEAM: How Does Yours Measure Up? The following framework of characteristics focuses on attributes that are within the control of investigators and their
More informationCompliance Program Guidance Manuals (CPGMs) -1-
Inspector s Preparation for a CI Inspection: FDA Compliance Program & the Records Inventory Jean Toth-Allen, Ph.D. APEC GCP Inspection Workshop May 28, 2008 Compliance Program Guidance Manuals (CPGMs)
More informationGood Clinical Practice
Clinical Site Monitoring DMID/ICSSC 10/7/08 1 Monitoring ICH E6 5.18.1 The purpose of monitoring is to ensure that: The rights and well-being of subjects are being protected The data are accurate, complete
More informationOFFICE FOR RESEACH PROCEDURE. Site Initiation and Close-out
OFFICE FOR RESEACH PROCEDURE Site Initiation and Close-out 1. Purpose: To describe the procedures related to site initiation and close-out of a clinical trial. 2. Scope: Applicable to all phases of clinical
More informationRisk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight
Risk-Based Monitoring: How Can It Be Implemented For More Effective Study Oversight Lisa Marie Saldanha Senior Director & Head of Operations Real World Insights Asia Singapore Research & Ethics Conference
More informationHuman Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents
Guidance for s Regulatory File Essential s All principal investigators must maintain a regulatory binder or file system, which contains all study documentation. These records may be reviewed at the time
More informationI. Purpose. II. Definitions. Last Approval Date
Investigational Drugs and Biologics Page 1 of 13 I. Purpose The purpose of this policy is to establish procedures for the proper control, storage, use and handling of investigational drugs and biologics
More informationCode break is also known as breaking the blind and involves un-blinding a participant so that the treatment allocation is made known.
1. INTRODUCTION This SOP has been produced in accordance with Medicines for Human Use (Clinical Trials) Regulations 2004. This SOP will outline the procedure for breaking the study code in a NUH sponsored
More informationResearch Study Close-down and Archiving Procedures
Title: Research Study Close-down and Archiving Procedures Outcome Statement: To inform researchers of the process for closing down research studies, retaining and storing research materials in the Trust.
More informationStandard Operating Procedure. GCP Auditing of Research Studies. SOP effective: 23rd January 2018 Review date: 23rd January 2020
Standard Operating Procedure SOP number: SOP full title: SOP-JRO-16-005 GCP Auditing of Research Studies SOP effective: 23rd January 2018 Review date: 23rd January 2020 SOP author signature: Signed copy
More informationDate: 21 st May 2014 Version: 5 Page 1 of 11. Principal Author Name D. Skelhorn Signature: D. Skelhorn Date: 22 nd May 2014
Date: 21 st May 2014 Version: 5 Page 1 of 11 STANDARD OPERATING PROCEDURE FOR MONITORING CLINICAL TRIALS (NWORTH 3.07) Approvals Principal Author Name D. Skelhorn Signature: D. Skelhorn Date: 22 nd May
More informationConducting Clinical Trials of Investigational Medicinal Products
Title: Outcome Statement: Written By: Reviewed By: Conducting Clinical Trials of Investigational Medicinal Products Researchers in the Trust and research partners will be informed about the procedures
More informationDocument Number: SOP/RAD/SEHSCT/003 Page 1 of 9 Version 2.0
Standard Operating Procedures (SOP) Research and Development Office Title of SOP: Archiving Study Documents SOP Number: 3 Version Number: 2.0 Supercedes: 1.0 Effective date: August 2013 Review date: August
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
SOP #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional responsibilities
More informationDate : Date of start of procedure: Authorisation/ positive opinion :
Substantial Amendment Notification Form (Cf. Section 3.7.b of the Detailed guidance on the request to the competent authorities for authorisation of a clinical trial on a medicinal product for human use,
More informationStandard operating procedures (SOPs) are
Standard Operating Procedures in Clinical Research: A Beginner s Guide Michael R. Hamrell a, * and Bruce Wagman b a MORIAH Consultants, Yorba Linda, CA, USA b MDS Pharma Incorporated, Sentry Parkway, WestBlue
More informationHigh Quality or Poor Quality DB
The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. ( DIA ), its directors, officers,
More informationQP 02 Audit and Certification Procedure
1. AUDIT PROGRAMME [9.1.1] The audit programme shall be conducted in stages within a 3-year certification cycle as follows; Initial audit: Two stage process Surveillance audit: Conducted in the first and
More informationOCTC 2012 CRO Selection
OCTC 2012 CRO Selection Colin Macaulay Viron Therapeutics Inc. 15 Nov 2012 Viron Therapeutics Inc. Virtual Biotech Company (6) Phase 2a (48 pt) clinical trial in acute coronary syndrome (ACS) completed
More informationQUALITY AGREEMENT. The following Agreement has been concluded between
QUALITY AGREEMENT The following Agreement has been concluded between LLC LABORATORIES The contract laboratory and service provider 1625 Trinity Dr., Unit 11 Mississauga, Ontario Canada L5T 1W9 Hereinafter
More informationIRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010
IRB-GCP and Timelines Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October 11-14 th, 2010 1 Factors that affect Timelines Finalized Protocol Finalized
More informationFDA Audit Preparation
Duke University Office of Audit, Risk and Compliance (OARC) FDA Audit Preparation Margaret M. Groves, JD, CRA, CCRP, CHRC Associate Compliance Officer, Research Compliance Assurance (RCA) External audits
More informationStandard Operating Procedure: Obtaining Informed Consent from Competent Adults for Research Studies. SOP Number: UoA-NHSG-SOP-010 Version No: 2
Standard Operating Procedure: Obtaining Informed Consent from Competent Adults for Research Studies SOP Number: UoA-NHSG-SOP-010 Version No: 2 Author: Date: 27 th March 2015 (Carole Edwards, Lead Research
More informationUNIVERSITY OF LEICESTER, UNIVERSITY OF LOUGHBOROUGH & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH SUPPORT OFFICE
UNIVERSITY OF LEICESTER, UNIVERSITY OF LOUGHBOROUGH & UNIVERSITY HOSPITALS OF LEICESTER NHS TRUST JOINT RESEARCH SUPPORT OFFICE STANDARD OPERATING PROCEDURES University of Leicester (UoL) Research Governance
More information\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management
Five Content Areas Percent of Scored Test Items (Range) in Each Area This table shows the percent of scored test questions that are included in each major content area. Five Content Areas Ethical Principles
More informationEffective Date: 1 May 2017
4.0 PURPOSE / OBJECTIVE ICH GCP requires BaCT to implement and maintain quality assurance and quality control systems with written SOPs to ensure that trials are conducted and data are generated, documented
More informationClinical trials from CRA s point of view
Clinical trials from CRA s point of view Dr Jacek S Gregorczyk MPharmS, PhD Clinical Research Associate (CRA) at MDS Pharma Services UK office - a global CRO REGULATION of CLINICAL TRIALS World Medical
More informationSTANDARD OPERATING PROCEDURE
STANDARD OPERATING PROCEDURE Title Reference Number Archiving and the Destruction of Records SOP-RES-028 Version Number 2 Issue Date 08 th Dec 2015 Effective Date 22 nd January 2016 Review Date 22 nd January
More informationELEMENTS OF A DATA MONITORING PLAN
ELEMENTS OF A DATA MONITORING PLAN Definitions Data Monitoring: The regular evaluation of data and documentation collected during a study to ensure both adherence to the approved investigative plan and
More informationANNEX. CHAPTER I General principles
ANNEX REGULATIONS on the authorisation by the NMA of clinical trials/notification to the National Medicines Agency of non-interventional studies on medicinal products for human use in Romania CHAPTER I
More informationTrial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products
1 Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products SECTION TITLE DOCUMENTS 1. Contact List Including details of relevant study site staff, responsible
More informationIDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES
IDENTIFYING & MANAGING GCP COMPLIANCE RISKS FOR THE PHARMACEUTICAL, BIOTECH & DEVICE INDUSTRIES Karen Weaver Epstein, Becker & Green Health Care & Life Sciences Practice APPLICABLE REGULATIONS 21 CFR 312
More informationThis document provides guidelines for unblinding participants enrolled in IMPAACT clinical trials.
APPENDIX I UNBLINDING PROCEDURES... 1 I.1 Purpose... 1 I.2 Scope... 1 I.3 Definitions... 1 I.3.1 Blinding... 1 I.3.2 Unblinding... 2 I.3.3 Open-label or Unblinded Study... 2 I.4 Roles and Responsibilities...
More informationGuide for Manufacturers and Sponsors on Clinical Investigations Carried Out in Ireland
Guide for Manufacturers and Sponsors on Clinical Investigations Carried Out in Ireland AUT-G0095-1 15 AUGUST 2014 This guide does not purport to be an interpretation of law and/or regulations and is for
More information3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.
POLICY #: RCO-100 Page: 1 of 11 1. POLICY STATEMENT: An Overall Principal Investigator (PI) who holds an Investigational New Drug Application (IND) and who is the Sponsor of the research has additional
More informationImplications for Investigator Initiated Trials (IITs)- Risk Based Approaches in Managing Clinical Trials
Implications for Investigator Initiated Trials (IITs)- Risk Based Approaches in Managing Clinical Trials Lisa Marie Saldanha Senior Director & Head Academic Research & Delivery Solutions Real World Insights
More informationMonitorización del ensayo clínico
Monitorización del ensayo clínico Dr. Salvador Ribas Ribas E-mail: salvador.ribas@gmail.com III CURSO PARA INVESTIGADORES SOBRE NORMAS DE BUENA PRÁCTICA CLÍNICA (BPC) Tenerife, 16 de septiembre 2009 Definition
More informationTrial Protocol. Version 1.2. Effective date: 18 May Dr Sarah Duggan, CTU Manager. V May 2010 Update web links.
Trial Version 1.2 Effective date: 18 May 2010 Reviewed by: Approved by: Claire Daffern, QA Manager Dr Sarah Duggan, CTU Manager Revision Chronology: Effective Date Reason for change V1.2 18 May 2010 Update
More informationObjectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents
Data Management in Clinical Trials Introduction to the Principles and Practice of Clinical Research January 24, 2011 Diane St. Germain, RN, MS, CRNP Nurse Consultant Division of Cancer Prevention National
More informationHub Performance Assessment
Hub Performance Assessment Hub complex performance assessment will be assessed with a standardized report card mechanism. The report card draws on data quality reports, enrollment reports, and monitoring
More informationSponsor-Investigator Responsibilities In Clinical Trials
In Clinical Trials Margaret Huber, RN, BSN, CHRC Compliance Manager The lecturer has no conflicts for this presentation 9/23/2015 Objectives Define terms sponsor, investigator, and sponsor-investigator.
More informationQuality Assurance in Clinical Trials Introduction
Quality Assurance in Clinical Trials Introduction Doctor Catherine CORNU, Lyon clinical Investigation Centre EUDIPHARM December 2012 1 Delphine TEPPE-CROITROU - Catherine CORNU (Hospices Civils de Lyon)
More informationGood Clinical Practice. Martin Rose, MD, JD February 8, 2018 ASQ
Good Clinical Practice Martin Rose, MD, JD February 8, 2018 ASQ Disclaimer The views expressed in this presentation are those of the presenter and do not necessarily represent the official position of
More informationTrial Services. The allround trial specialist in cardiology Leading since cardialysis.com
Trial Services The allround trial specialist in cardiology Leading since 1983 cardialysis.com Trial design The key factor in achieving a successful clinical trial is to have a well-prepared, consistent
More informationStandard Operating Procedures
Standard Operating Procedures 6.5.1 Study Recruitment Version V2.2 Author/s Approved B Fazekas, S Kochovska D Currow Effective date 28/02/2018 Review date 31/12/2019 DO NOT USE THIS SOP IN PRINTED FORM
More informationHow to Set Up and Manage Quality Control and Quality Assurance
How to Set Up and Manage Quality Control and Quality Assurance Myriam Visschedijk 1, *, Rik Hendriks 2 and Katrien Nuyts 3 1 TNO Quality of Life, The Netherlands 2 Johnson & Johnson Pharmaceutical Research
More informationGood Clinical Practice Inspections Expectations for Compliance with Sponsor Responsibilities, Part II
Good Clinical Practice Inspections Expectations for Compliance with Sponsor Responsibilities, Part II IMB Clinical Trials Seminar, 19 th June 2012 Ms. Sinead Curran GCP/Pharmacovigilance Inspector 22/06/2012
More informationISRCTN: EudraCT Number: Sponsor Protocol Number: UCL 08/0350. Pharmacy Manual
The StAmP Trial: A Proof of Principle, double blind, Randomised Placebo-Controlled, Multi Centre Trial of Statins to Ameliorate Early Onset Pre-eclampsia. ISRCTN: 23410175 EudraCT Number: 2009-012968-13
More informationNEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES
NEWCASTLE CLINICAL TRIALS UNIT STANDARD OPERATING PROCEDURES SOP details SOP title: Statistical Validation of Clinical Trial Protocols and Case Report Forms SOP number: ST 001 SOP category: Statistics
More informationFERCI MODEL SOPs. Preparing for Ethics Committee Audit/ Inspection
Title: SOP Code: SOP 01/V1 [The IEC members (author/s, reviewer/s) and Chairperson will sign and date the SOP on this first page] Prepared by: Dr. Padmaja Marathe, FERCI Member Reviewed by: Dr. U. M. Thatte,
More informationR&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no:
Research as a Participating site STANDARD OPERATING PROCEDURE FOR OVERSIGHT SOP No: P08/PF2 V2 Effective Date: 31 st July 2013 Supersedes: P08/PF2 Revision Date: 31 st March 2014 Author: Position: Approved
More informationFDA Requirements for Clinical Investigations of Medical Devices: A Review for European Manufacturers
FDA Requirements for Clinical Investigations of Medical Devices: A Review for European Manufacturers Autumn Dawn Ediger, 1, * Birgit Limbach 2 and Dieter Dannhorn 3 1 Regulatory Affairs, Clinical QM and
More informationPrecision-Panc Master Protocol: Personalising treatment for pancreatic cancer.
Precision-Panc Master Protocol: Personalising treatment for pancreatic cancer. Initiation Slides (Version 1 Draft 2 : 30 th October 2017) Sponsor: NHS Greater Glasgow and Clyde Chief Investigators: Dr
More informationIBM Clinical Development Subscription
Service Description IBM Clinical Development Subscription This Service Description describes the Cloud Service IBM provides to Client. Client means the contracting party and its authorized users and recipients
More informationIBM Clinical Trial Management System for Sites
Service Description IBM Clinical Trial Management System for Sites This Service Description describes the Cloud Service IBM provides to Client. Client means the contracting party and its authorized users
More informationDemystifying Audits. Audits and Audit Preparation 5/23/2016. What is an Audit?
Demystifying Audits Darlene Kitterman, MBA Director, Investigator Support & Integration Services OCTRI May 26, 2016 Audits and Audit Preparation What is an Audit? A systematic and independent examination
More informationClinical trial databases are a crucial investment in clinical research. Part 4 - The "Life" of a Data Manager - Project Manager for the Database
Clinical trial databases are a crucial investment in clinical research Part 4 - The "Life" of a Data Manager - Project Manager for the Database Speakers: M.Duvenhage K. Laras S. Erari 12 Oct 2018 Overview
More informationSource And Regulatory Documentation for DMID Clinical Studies
Source And Regulatory Documentation for DMID Clinical Studies Walt Jones RN, MPH Nurse Consultant Clinical Monitoring Coordinator OCRA, DMID, NIAID November, 2007 Source Data Defined All information in
More informationSponsor/Investigator Responsibilities
Sponsor/Investigator Responsibilities Marian Serge, RN Division of Bioresearch Monitoring Office of Compliance Center for Devices and Radiological Health Food and Drug Administration Marian.Serge@fda.hhs.gov
More informationDANA-FARBER / HARVARD CANCER CENTER STANDARD OPERATING PROCEDURES FOR HUMAN SUBJECT RESEARCH TITLE
SOP #: DATA-101 Page: 1 of 5 1. POLICY STATEMENT: Case Report Forms (CRFs) are designed by the Clinical Trials Research Informatics Office (CTRIO) in collaboration with the Sponsor, Overall PI, designated
More informationK E M R I STANDARD OPERATING PROCEDURE FOR ROUTINE AND FOR- CAUSE AUDITS
In Search Of Better Health K E M R I STANDARD OPERATING PROCEDURE FOR ROUTINE AND FOR- CAUSE AUDITS REF NO: KEMRI/SERU/SOP/PI/R&FCAC Version: 1 PAGE: 2 of 10 Document Control Schedule Name of department:
More informationQuality Site Visit Report FGK Clinical Research (FGK) GmbH, Munich Germany. Audit No. CT6018. Date of Audit: 3rd to 5th May 2017
Quality Site Visit Report FGK Clinical Research (FGK) GmbH, Munich Germany Head Office Address FGK Clinical Research GmbH Heimeranstrasse 35, 80339 Munich, Germany Research Centre Address FGK Clinical
More informationEnsuring Quality of Regulatory Clinical Documents
Ensuring Quality of Regulatory Clinical Documents Henry Li *, Kim Hanna and Steve Petteway Talecris Biotherapeutics, Research Triangle Park, North Carolina, USA Summary A large number of clinical documents
More informationDevelopment Safety Update Report Guidance
Development Safety Update Report Guidance This document provides instructions for the preparation and submission of a Development Safety Update Report (DSUR) for a Clinical Trial of an Investigational
More information